Product Description
A methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/indoximod)
Mechanisms of Action: IDO1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Double Point Ventures
Company Location: Western America
Company Founding Year: 2020
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Brain Cancer|Ependymoma|Glioblastoma|Medulloblastoma|Primitive Neuroectodermal Tumors
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05106296 |
GCC2020 | P1 |
Recruiting |
Medulloblastoma|Brain Cancer|Glioblastoma|Ependymoma|Primitive Neuroectodermal Tumors |
2028-03-30 |
2026-01-10 |
Primary Completion Date|Primary Endpoints |